Skip to content

Author

Lucie Dequiedt

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

TiSAM: fusing spatial and histopathology foundation models for whole-slide image segmentation

Semantic segmentation of whole-slide images (WSIs) quantifies tissue composition and architecture, but existing models require extensive annotation and lose accuracy as the number of tissue classes increases or on heterogeneous, cross-scanner datasets. Here, we present the Tissue Segment Anything Model (TiSAM), which f...

Zhi-Yuan Ding, Lucie Dequiedt, Marta Forjaz et al. · 0 citations
Open access Nov 2026

Explainable Multimodal Prognostic Modeling Uncovers New Clinically Relevant Pathological Features in a Multi-Institutional Pancreatic Neuroendocrine Tumor Cohort

Although many patients with a well-differentiated pancreatic neuroendocrine tumor (PanNET) are cured after surgical resection, it is hard to predict outcome in these patients. Current prognostic assessment relies largely on Ki-67 proliferation index, tumor stage, and established adverse pathologic features, such as vas...

Arrun Sivasubramanian, M. Salimian, Jithin Reddy Vennapusa et al. · 0 citations
Sep 2026

Abstract A090: Quantitative evaluation of changes to healthy pancreatic microanatomy across the human lifespan

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, with a five-year survival rate near 10%. The rarity of PDAC contrasts the abundance of its primary precursor lesion, pancreatic intraepithelial neoplasia (PanIN). PanIN is known to be common in surgically resected pancreas and to exist even in normal don...

Valentina Matos-Romero, Kara A. Lombardo, Daniela Higuera-Garrido et al. · 0 citations
Sep 2026

Abstract A032: Elucidating the role of p53 in suppressing pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at advanced, metastatic stages, emphasizing the need to study the earliest events in disease progression. The tumor suppressor p53 strongly opposes PDAC development and is mutated in nearly 75% of cases, yet how wild-type p53 functions to delay cancer on...

Jessica L. Mann, Kathryn J. Hanson, Lucie Dequiedt et al. · 0 citations
Sep 2026

Abstract IA007: Getting ahead of the tumor: Interception approaches for pancreas cancer

Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...

Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.